In a regulatory filing, the company said that Jain’s resignation will be effective from the close of business hours on 30 September 2025.
Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives.
The company’s consolidated net profit surged 87.1% to Rs 160.69 crore despite 6.9% decline in revenue from operations to Rs 606.54 crore in Q1 FY26 over Q1 FY25.
Shares of Epigral shed 0.67% to Rs 1,785 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."